Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3402 Monotherapy in MDS and CMML
NCT05690425Phase 1Unknown
- Sponsor
- BioCity Biopharma
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BC3402 in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by BioCity Biopharma. Primary endpoint: Incidence of Dose Limiting Toxicities at 28 days. Status: unknown.
02
Drugs
BC3402
03
Conditions
myelodysplastic syndromes (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05690425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690425.